Expression and Significance of miR-654-3p/ARL4C in Patients with Glioma
Abstract Background: ADP-ribosylation-like factor4C (ARL4C) is overexpressed in several cancer tissues and is involved in cancer development. Increasing evidence reveals that aberrant microRNAs (miRNAs) expression play a crucial role in the tumorigenesis of cancers. Nevertheless, the exact mechanism that regulates ARL4C expression in glioma has not been fully elucidated. The aim of this study was to investigate expression and significance of miR-654-3p/ARL4C in glioma.Methods: CGGA and TCGA databases were used to study the prognosis role of miR-654-3p, ARL4C and the relationship between ARL4C and pathological grade in gliomas. Real-time quantitative PCR was performed to detect the levels of miR-654-3p and ARL4C in glioma tissues. CCK-8 and colony formation experiments were used to observe the effects of miR-654-3p and ARL4C on the proliferation of U87 cells.Results: CGGA database and TCGA database both showed that the level of ARL4C was increased along with the WHO grades of glioma, and patients with high ARL4C had lower IDH mutation ratio, older age and poor overall survival (OS) compared with patients with low ARL4C. The clinical features in patients with high miR-654-3p showed the opposite trend compared with patients with high ARL4C. In vitro experiments showed that overexpression of ARL4C promoted cell proliferation in U87 cells. Dual-luciferase reporter gene assays showed that ARL4C was the target gene of miR-654-3p, and miR-654-3p mimics could inhibit the cell proliferation of U87 cells, and ARL4C partly counteracted the role of miR-654-3p in U87 cells.Conclusions: miR-654-3p/ARL4C is associated with pathological grade of glioma, and patients with high ARL4C or low miR-654-3p have shorter OS. miR-654-3p/ARL4C may serve as a prognostic factor in patients with glioma and new potential therapeutic target.